Statera Biopharma Company Description
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis.
The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers.
It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.
The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021.
Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. operates as a subsidiary of Biostax Corp.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 46 |
| CEO | Michael Handley |
Contact Details
Address: 2580 East Harmony Road, Fort Collins, Delaware 80528 United States | |
| Phone | 888 613 8802 |
| Website | staterabiopharma.com |
Stock Details
| Ticker Symbol | STAB |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US8575611046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael Kevin Handley | Chief Executive Officer, President and Chairman of the Board |
| Christopher Zosh | Executive Vice President of Finance, Interim Principal Financial Officer and Interim Principal Accounting Officer |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer |